ATE369141T1 - Zellvermittelte genverabreichung durch verwendung von aus muskeln derivierten zellen zur behandlung der knochen-verwandten verletzung oder störung - Google Patents

Zellvermittelte genverabreichung durch verwendung von aus muskeln derivierten zellen zur behandlung der knochen-verwandten verletzung oder störung

Info

Publication number
ATE369141T1
ATE369141T1 AT99920202T AT99920202T ATE369141T1 AT E369141 T1 ATE369141 T1 AT E369141T1 AT 99920202 T AT99920202 T AT 99920202T AT 99920202 T AT99920202 T AT 99920202T AT E369141 T1 ATE369141 T1 AT E369141T1
Authority
AT
Austria
Prior art keywords
muscle
derivated
disorder
bone
treat
Prior art date
Application number
AT99920202T
Other languages
English (en)
Inventor
Michael Chancellor
Johnny Huard
Original Assignee
Univ Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22181500&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE369141(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Pittsburgh filed Critical Univ Pittsburgh
Application granted granted Critical
Publication of ATE369141T1 publication Critical patent/ATE369141T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
    • C12N5/0659—Satellite cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/105—Insulin-like growth factors [IGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/113—Acidic fibroblast growth factor (aFGF, FGF-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT99920202T 1998-05-01 1999-04-30 Zellvermittelte genverabreichung durch verwendung von aus muskeln derivierten zellen zur behandlung der knochen-verwandten verletzung oder störung ATE369141T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8391798P 1998-05-01 1998-05-01

Publications (1)

Publication Number Publication Date
ATE369141T1 true ATE369141T1 (de) 2007-08-15

Family

ID=22181500

Family Applications (2)

Application Number Title Priority Date Filing Date
AT99920202T ATE369141T1 (de) 1998-05-01 1999-04-30 Zellvermittelte genverabreichung durch verwendung von aus muskeln derivierten zellen zur behandlung der knochen-verwandten verletzung oder störung
AT05000057T ATE414524T1 (de) 1998-05-01 1999-04-30 Verwendung von myoblasten zur herstellung eines medikaments zur behandlung der stressbedingten harninkontinenz

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT05000057T ATE414524T1 (de) 1998-05-01 1999-04-30 Verwendung von myoblasten zur herstellung eines medikaments zur behandlung der stressbedingten harninkontinenz

Country Status (8)

Country Link
EP (3) EP1604674B1 (de)
AT (2) ATE369141T1 (de)
AU (1) AU3775799A (de)
CA (1) CA2330660C (de)
DE (2) DE69939956D1 (de)
DK (2) DK2075002T3 (de)
ES (2) ES2419029T3 (de)
WO (1) WO1999056785A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115417B1 (en) 1998-05-01 2006-10-03 Chancellor Michael B Soft tissue and bone augmentation and bulking utilizing muscle-derived progenito compositions, and treatments thereof
US6866842B1 (en) 1998-05-01 2005-03-15 University Of Pittsburgh Muscle-derived cells (MDCs) for treating muscle-or bone-related injury or dysfunction
US8211423B2 (en) 2006-11-28 2012-07-03 University Of Pittsburgh Muscle derived cells for the treatment of cardiac pathologies and methods of making and using the same
US6706682B2 (en) * 1999-01-21 2004-03-16 The Trustees Of Columbia University In The City Of New York Uses of vascular endothelial growth factor in the treatment of erectile dysfunction
US6315992B1 (en) 1999-06-30 2001-11-13 Tissuegene Co. Generating cartilage in a mammal using fibroblasts transfected with a vector encoding TGF-β-1
CN101972275A (zh) * 1999-05-03 2011-02-16 组织基因股份有限公司 使用TGF-β的基因治疗
US7338655B1 (en) 1999-06-30 2008-03-04 Tissuegene, Inc. Gene therapy using TGF-β
AU6920800A (en) * 1999-08-19 2001-03-13 Stem Cell Pharmaceuticals, Inc. Tgf-alpha polypeptides, functional fragments and methods of use therefor
US20020193301A1 (en) 1999-08-19 2002-12-19 Stem Cell Pharmaceuticals, Inc. TGF-alpha polypeptides, functional fragments and methods of use therefor
AU5159901A (en) * 2000-04-14 2001-10-30 Univ Pittsburgh Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof
FR2810045B1 (fr) * 2000-06-07 2004-09-03 Assist Publ Hopitaux De Paris Procede d'obtention de population cellulaires caracterisees d'origine musculaire et utilisations
US20020155096A1 (en) * 2001-02-23 2002-10-24 Chancellor Michael B. Rapid preparation of stem cell matrices for use in tissue and organ treatment and repair
ATE482713T1 (de) * 2003-04-25 2010-10-15 Univ Pittsburgh Von muskeln stammende zellen (mdcs) zur förderung und verbesserung der nervenreparatur und - regeneration
RU2286790C1 (ru) * 2005-03-16 2006-11-10 Государственное учреждение Научный центр акушерства, гинекологии и перинатологии Российской академии медицинских наук Способ лечения стрессового недержания мочи
WO2008076435A1 (en) 2006-12-18 2008-06-26 University Of Pittsburgh Muscle derived cells for the treatment of gastro-esophageal pathologies and methods of making and using the same
US20100158875A1 (en) 2006-12-18 2010-06-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Muscle derived cells for the treatment of gastro-esophageal pathologies and methods of making and using the same
ES2678416T3 (es) 2007-01-11 2018-08-10 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Células derivadas de músculo para el tratamiento de patologías de las vías urinarias y métodos de fabricación y uso de las mismas
CA2691361A1 (en) * 2007-06-15 2008-12-24 Ethicon, Inc. Tissue fragment compositions for the treatment of incontinence
EP2328596B1 (de) * 2008-08-18 2019-03-06 University of Pittsburgh - Of the Commonwealth System of Higher Education Knochenaufbau anhand von vorläuferzusammensetzungen aus muskeln in biokompatibler matrix und behandlungen
US9700581B2 (en) 2012-09-10 2017-07-11 Wake Forest University Health Sciences Urine stem cells for skeletal muscle generation and uses thereof
EP3511412A1 (de) 2018-01-12 2019-07-17 Genethon Genetisch modifizierte hematopoietische stammzellen als plattform fuer systemische proteinexpression
US10610280B1 (en) 2019-02-02 2020-04-07 Ayad K. M. Agha Surgical method and apparatus for destruction and removal of intraperitoneal, visceral, and subcutaneous fat
WO2020238961A1 (en) * 2019-05-29 2020-12-03 Institute Of Zoology, Chinese Academy Of Sciences Compositions and use of engineered myogenic cells
EP4627056A1 (de) 2022-12-01 2025-10-08 Universität Zürich Verfahren zur herstellung einer massenkultur von muskelvorläuferzellen (mps) und verwendungen davon

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5130141A (en) * 1988-05-24 1992-07-14 Law Peter K Compositions for and methods of treating muscle degeneration and weakness
US5538722A (en) 1989-06-13 1996-07-23 Stanford University Isolation, growth, differentiation and genetic engineering of human muscle cells
US5658565A (en) 1994-06-24 1997-08-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Inducible nitric oxide synthase gene for treatment of disease
EP0670902A1 (de) 1992-11-25 1995-09-13 University Of Pittsburgh Of The Commonwealth System Of Higher Education FÜR MENSCHLICHE INDUZIERBARE STICKSTOFFOXYDESYTHASE KODIERENDE cDNA UND VERFAHREN ZUR HERSTELLUNG DAVON
US5594032A (en) * 1994-11-10 1997-01-14 Gonzalez-Cadavid; Nestor F. Amelioration of human erectile dysfunction by treatment with iNOS, inducers of iNOS or iNOS cDNA
EP1407788A2 (de) * 1994-12-13 2004-04-14 Peter K. Law Myoblast-Therapie für Säugetierkrankheiten
US6150338A (en) * 1997-02-13 2000-11-21 Albert Einstein College Of Medicine Of Yeshiva University Gene therapy for alleviating erectile dysfunction

Also Published As

Publication number Publication date
EP1113807B1 (de) 2007-08-08
EP2075002B1 (de) 2013-02-13
EP1604674B1 (de) 2008-11-19
ES2419029T3 (es) 2013-08-19
DK2075002T3 (da) 2013-05-21
EP1604674A2 (de) 2005-12-14
CA2330660C (en) 2012-04-10
AU3775799A (en) 1999-11-23
CA2330660A1 (en) 1999-11-11
DE69936785D1 (de) 2007-09-20
ATE414524T1 (de) 2008-12-15
WO1999056785A3 (en) 2001-04-19
EP2075002A3 (de) 2009-07-08
WO1999056785A2 (en) 1999-11-11
EP2075002A2 (de) 2009-07-01
ES2319660T3 (es) 2009-05-11
DK1604674T3 (da) 2009-03-23
EP1604674A3 (de) 2005-12-21
DE69939956D1 (de) 2009-01-02
EP1113807A2 (de) 2001-07-11

Similar Documents

Publication Publication Date Title
DE69936785D1 (de) Zellvermittelte genverabreichung durch verwendung von aus muskeln derivierten zellen zur behandlung der knochen-verwandten verletzung oder störung
WO2007079203A3 (en) Treatment for cutaneous t cell lymphoma
PL342078A1 (en) Inhibition of raf kinase using symmetrical and dissymmetrical substituted dimethylureas
BRPI0411255A (pt) composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto
BR0314611A (pt) Compostos de tiazol para o tratamento de distúrbios neurodegenerativos
EP2284267A3 (de) Modulation der expression von diacylglycerin-acyltransferase 2
ATE140918T1 (de) Derivate in der vitamin d-reihe mit modifikationen in der 20 position, verfahren zu ihrer herstellung, zwischenprodukte für dieses verfahren, diese derivate enthaltende pharmazeutische präparate sowie deren verwendung zur herstellung von arzneimitteln
CA2468747A1 (en) Use of pramipexole to treat amyotrophic lateral sclerosis
DE69229442D1 (de) Substituierte dibenzooxazepin-verbindungen, pharmazeutische zusammensetzungen und verfahren zur verwendung
IL192287A0 (en) Pharmaceutical compositions and methods for use
DE69916632D1 (de) Verwendung von zimtsäurederivaten zur herstellung eines medikamentes zur vorbeugung oder behandlung von erkrankungen die durch einen hohen blutfettspiegel bedingt sind
ATE296880T1 (de) Zyklische nukleotid-vermittelte ionenkanal verbindungen aus hirn und herz sowie deren verwendungen
ATE293976T1 (de) Verbindungen enthaltend s-tofisopam sowie verwendung dieser verbindungen zur herstellung eines medikamentes zur behandlung oder prophylaxe von krämpfen und anfällen
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
BR9916391A (pt) Compostos de triazineona para o tratamento de doenças causadas por sarcosiste, neopora e toxoplasma
ATE312626T1 (de) Mucoadhäsive, wärmeaktivierbare zubereitung als träger für medikamente
BR9607443A (pt) Composto de 4-aminotetraidrobenzisoxazol ou-isatiazol composição farmacêutica e utilização do composto
BRPI0409683A (pt) 5-hidroxiindóis com grupos n-óxido e seu emprego como agentes terapêuticos
DE50108711D1 (de) Verwendung von substituierten 6-dimethylaminomethyl-1-phenyl-cyclohexanverbindungen zur therapie der harninkontinenz
DE502005008878D1 (de) Para-alkyl-substituierte n-(4-hydroxy-3-methoxy-benzyl)-zimtsäeureamide und deren verwendung zur herstellung von arzneimitteln
BRPI0408238A (pt) anticorpo, método de detectar cáncer, conjunto para detecção de cáncer, e, composição farmacêutica para tratar cáncer
ATE345121T1 (de) Verwendung von konjugierter linolsäure zur behandlung der erkältung
ATE308513T1 (de) Naphthamid-neurokinin antagonisten zur verwendung als medikamente
BR0316392A (pt) Processo para preparar ácido indan-1,3-dicarboxìlico
WO2002094876A3 (en) Methods and compositions for treating respiratory mucin production associated disease conditions

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties